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Within the repeating As, Cs, Gs and Ts of the human genome is the 
blueprint for all the organs and tissues of our bodies, from skin and 
hair to the complex neuronal pathways that make up the brain. This 
information is contained in six billion base pairs of DNA that reside 
in the nucleus of every nucleated cell, half the information from our 
mothers and half from our fathers. Since the launch of the human 
genome project more than 20 years ago, understanding of DNA and its 
various interactions that make us who we are has increased exponentially.
It has also been discovered that even small, seemingly insignificant 
changes in the sequence of our DNA can have drastic consequences. 
The search is on for tools that will allow these mutations to be 
changed to correct the DNA sequence, in much the same way as one 
might correct a spelling error in a manuscript before publication – 
editing the genome, if you will.
Unpacking the basics
The term ‘editing’ implies a precise and predictable process by which 
the genome might be changed, and for the past 10 years – at least – 
the search for the best tool to do this has been on.
Identification of a tool to change the genome started as whisper, 
but during the past 5 years it has grown to a deafening roar and at last 
there seems to be a technology with genuine potential to revolutionise 
the field of genome engineering. Clustered regularly interspaced 
palindromic repeat (CRISPR)-associated genes (CRISPR-Cas) have 
emerged as a novel class of sequence-specific endonucleases with 
unparalleled flexibility, cost-effectiveness and ease of application.
This technology is derived from a bacterial pathway that allows the 
organism to detect and degrade invading genetic material. Although there 
are three naturally occurring types of CRISPR-Cas technologies, only the 
type II system has been proven to be relevant to the genome engineering 
field so far. Initial work by Jinek et al.[1] has seen the progression of 
CRISPR-Cas from an interesting bacterial phenomenon to a potentially 
useful molecular tool.Later work by Cong et al.[2] ushered CRISPR-Cas to 
the forefront of the gene-editing technology race.In 3 years, CRISPR-Cas 
has outshone, outpaced and outperformed the majority of the other gene 
editing technologies, including the broadly applied zinc finger nucleases 
and transcription activator-like effector nucleases.
Acknowledging flaws
This is not to say that CRISPR-Cas has been without its problems. 
One of the major considerations is the predictability and accuracy 
of targeted outcomes of the DNA cleavage events, and in the earliest 
iterations of this technology CRISPR-Cas was a dismal failure.
Early estimates of unintentional and potentially catastrophic 
cleavage events suggested that the sequence specificity for targeting 
might be off by as much as much as 25%, with DNA double-strand 
breaks occurring at sites with as little as 75% sequence homology to 
the targeted locus.[3] In a field reliant on absolute precision with zero 
tolerance for error, this was an early setback for the technology.
However, diligent investigation has yielded important results, and 
in early 2016 two research groups from the Broad Institute identified 
four novel mutations in the Cas9 protein that rendered Cas9 totally 
reliant on 100% sequence homology to facilitate cleavage.[4] These 
groups used next-generation sequencing of the whole genome to 
establish that no unintended breaks had been introduced at other 
sites – so-called ‘off-target’ effects. This has potentially delivered the 
Holy Grail for gene editing, a technology that is now precise and 
accurate with no potentially mutagenic side-effects, and with this 
quantum leap in technology we can finally start looking to clinical 
applications.
Therapeutic applications of  
CRISPR-Cas
Genome editing has already broadened our ability to investigate the 
contribution of specific genes and mutations to disease by facilitating 
the creation of accurate cellular and animal models. This is certainly 
where CRISPR-Cas9 has cut its teeth, while several groups have also 
worked to improve the targeted activity of CRISPR-Cas9 and its 
overall safety.
This is by no means where the application of gene editing ends. 
A particularly attractive application is correction of underlying 
mutations to treat diseases, particularly in conditions that have 
proved to be refractory to traditional therapies.
Genome editing-based therapy can be accomplished in a number 
of ways, including correction or inactivation of deleterious mutations, 
introduction of protective mutations, addition of therapeutic 
transgenes and disruption of viral DNA.
Work is already underway across the globe to translate the potential 
of targeted gene therapy into viable clinical applications. This includes 
the recapitulation of the Δ32 mutation in the CCR5 gene, rendering 
cells immune to HIV;[5] the correction of deleterious mutations in 
the DNA that result in a number of inherited diseases, including 
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cystic fibrosis, Fanconi’s anaemia, β-thalassaemia[6] and Duchenne’s 
muscular dystrophy;[7] the integration of exogenous DNA that returns 
function to mutated proteins, where the mutations are too large 
to allow simple correction; the integration of protective genes that 
confer therapeutic potential to specific cell types; and therapeutics 
that would allow us to target and eliminate viral DNA such as 
HIV, reducing the burden of latent viral infections.[8] These studies 
have produced promising results, and the number of indications 
under investigation for gene editing is growing exponentially. Gene 
editing, and in particularly CRISPR-Cas technologies, look set to 
revolutionise the treatment of a wide variety of diseases in the near 
future.
Ethical questions
As with any progressive idea, the implementation of genome 
engineering is not without ethical and regulatory concerns.
Many of the breakthroughs in the genome engineering sphere have 
been viewed as huge scientific triumphs, but the translation of these 
technologies from the bench to the bedside is not without ethical, 
legal and social issues requiring vigorous debate.
First, can we predict the ultimate consequences of gene editing on 
the evolution of the human race? Mutation is the backbone of the 
evolutionary process, and developing a technology that introduces 
novel mutations while repairing others could have a profound effect 
on the direction of human natural history. The only answer to this 
question seems to be that time will tell. We should, however, make 
informed decisions around the types of genome editing we wish to 
undertake.
Second, should we allow embryonic/germline engineering, or 
only permit somatic cell engineering? The genome engineering 
community has spent much time debating this point, and at the 
end of 2015 reached a consensus at a meeting in Washington that 
involved the global community. Genome engineering for research 
purposes should be allowed in both somatic and embryonic cells, 
but with important ethical concerns and the concerns around safety, 
genome engineering for therapeutic applications should be restricted 
to somatic cells.
Moreover, human beings have the right to health, and as such it is 
imperative that we find ways to ensure that genome engineering as a 
therapeutic modality is accessible to all people and not only to those 
who can afford it.
Along with the ethical concerns around genome engineering, this 
rapidly evolving field also presents novel regulatory questions. As 
more and more clinical applications are developed, so the burden 
on developing processes for their evaluation by various regulatory 
boards will increase.
How will trials select control groups? Will it be ethical to 
engineer healthy individuals? How will we compensate for unknown 
side-effects? What will the threshold be for acceptable off-target 
mutations? These and other questions will need to be answered 
before gene editing can be applied in a therapeutic setting.
The future
In conclusion, despite a number of important ethical and practical 
concerns, genetic engineering remains set to shape the future of 
molecular medicine.
This technology has the potential to fundamentally alter the way 
we treat diseases that have a genetic/genomic component, and with 
careful consideration, continued discussion and improved sharing of 
information on a global scale, CRISPR-Cas looks as if it may become 
one of the most valuable medicinal tools of the 21st century.
CRISPR-Cas was only discovered 3 years ago, and while navigating 
the road to its clinical application is likely to require a great deal 
of effort, one can only imagine what the landscape of genome 
engineering will look like in another 5 or even 10 years.
Sources of funding. South African Medical Research Council University 
Flagship and Extramural Unit awards.
1. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in 
adaptive bacterial immunity. Science 2012;337(6096):816-821. DOI:10.1126/science.1225829
2. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 
2013;339(6121):819-823. DOI:10.1126/science.1231143
3. Lin Y. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA 
and guide RNA sequences. Nucleic Acids Res 2014;42(11):7473-7485. DOI:10.1093/nar/gku402
4. Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable 
genome-wide off-target effects. Nature 2016;529(7587):490-495. DOI:10.1038/nature16526
5. Kang H, Minder P, Park MA, Mesquitta W-T, Torbett BE, Slukvin II. CCR5 disruption in induced 
pluripotent stem cells using CRISPR/Cas9 provides selective resistance of immune cells to CCR5-
tropic HIV-1 virus. Mol Ther Acids 2015;4(12):e268. DOI:10.1038/mtna.2015.42
6. Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs 
using CRISPR/Cas9 and piggyBac. Genome Res 2014;24(9):1526-1533. DOI:10.1101/gr.173427.114
7. Mendell JR, Rodino-Klapac LR. CRISPR/Cas9 treatment for Duchenne muscular dystrophy. Cell Res 
2016;26(5):513-514. DOI:10.1038/cr.2016.28
8. Kennedy EM, Kornepati AVR, Cullen BR. Targeting hepatitis B virus cccDNA using CRISPR/Cas9. 
Antiviral Res 2015;123:188-192. DOI:10.1016/j.antiviral.2015.10.004
Accepted 30 May 2016.
